Cardiff Lexington Corp (CDIX) stock

CDIXOTCServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 0/30

$0.04−0.01 (-25.53%)

Close on Oct 19, 2026Market cap $550.31KP/E –Yield –

Cardiff Lexington r&d expenses

Research and development expenses are spending on new products and technology.

Cardiff Lexington has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Cardiff Lexington's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3 reverse split on Jan 12, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CDIX.

Revenue growth-23.7% · median -26.8%

Operating margin-25.2% · median -65.1%

Net margin-126.4% · median -130.7%

Advertisement
300 × 250

See a number that looks wrong?